- Core Business Continues to Grow Strongly -
- Positive results for Phase III Pollinex Quattro Ragweed trial announced today -

Allergy Therapeutics plc (AIM: AGY), the allergy vaccination company with a growing sales
base, a substantial manufacturing facility and a European sales and marketing infrastructure,
announces preliminary results for the year ended 30 June 2008.

In a separate press release issued this morning, Allergy Therapeutics has also announced
positive results from its Phase III Pollinex Quattro Ragweed trial.

Financial Highlights

• Net sales increased by 21% to £31 million (2007: £25.7m)

   o Pollinex® Quattro named-patient sales increased by 25% to £11.9 million

   o £2.7 million milestone payment received from Canadian licensee

• Operating profit before R&D of £0.7 million (2007: loss of £0.9m)

• R&D expenditure reduced to £16.3 million (2007: £25.3m)

• Operating loss reduced to £15.6 million (2007: £26.3m)

• Cash of £2.3 million at period end and access to further funds

Operational Highlights

• Successful completion of the two largest Phase III studies ever undertaken in allergy
vaccination
   o Incontrovertible proof of efficacy of Pollinex Quattro Grass and Ragweed
   o G301 trial the first ever successfully conducted large scale, double blind,
placebo controlled trial in allergy vaccination based in N America to meet
primary efficacy endpoint

• Clear route to registration in Europe for Pollinex Quattro Grass

• Successful MHRA audit at both facilities in February 2008


For further information

Allergy Therapeutics
Keith Carter, Chief Executive 
Ian Postlethwaite, Finance Director 
+44 (0) 1903 844 7200

Financial Dynamics 
David Yates 
Ben Brewerton
+44 (0) 207 831 3113


Click here to download full PDF